MGC Pharma develops and markets medicines using compounds derived from cannabis and other plant-based sources.
MCG recently reported its second quarter (Q2) fiscal 2022 (FY22) cash flow and sales numbers.
In this report, Proactive Research Analyst Robin Davison reviews the timing of the clinical trials programme.
MGC recognised medicinal cannabis sales of A$1.3mln in H1FY22 (to 31 December) and A$1.1mln in sales of ArtemiC (the food supplement to relieve COVID-19 symptoms that is distributed by Swiss PharmaCan (TSX-V:MJN)).
Click here to read the report
